Cutaneous Mastocytosis Market
Global Market Study on Cutaneous Mastocytosis Treatment: Significant Efforts for Novel Drug Development to Treat Infants Likely to Boost Growth
Cutaneous Mastocytosis Market Segmented By antihistamines, steroids, mast cell stabilizers, Adrenergic Agonists, Photo-chemotherapy Drugs Type in oral, injectables, topical Route with maculopapular cutaneous mastocytosis, diffuse cutaneous Mastocytosis and solitary cutaneous mastocytoma Indication
Increasing Diagnosis Further Improving the Treatment Seeking Rate
Cutaneous mastocytosis, a relatively rare disease, generally affects children below two years of age, and hence, diagnosis becomes difficult. Limited awareness among healthcare professionals as well as the general population delays the diagnosis and treatment of cutaneous mastocytosis.
In the last decade, various non-profit organizations as well as government organizations have come forward to increase awareness about cutaneous mastocytosis, and since then, the diagnosis rate has increased substantially.
Increasing awareness about the symptoms and treatment options has compelled the parents of newborns to visit physicians, which in turn, is increasing the diagnosis rate as well as treatment seeking rate in case of cutaneous mastocytosis. In 2016, the WHO updated the diagnostic criteria for cutaneous mastocytosis, which further helped in improving the diagnosis rate of the disease.
Find Out More about the Report Coverage
- Bausch Health Companies Inc.
- Pfizer Inc.
- Merck & Co., Inc.
- Mylan N.V.
- EPI Health, LLC.
- kaleo, Inc.
- Teva Pharmaceutical Industries Ltd.
- Novartis AG
- Bayer AG
- Johnson & Johnson
Substantial Ongoing Efforts in Pathogenesis and Treatment of Cutaneous Mastocytosis
In the last decade, substantial efforts by various organizations have been made in order to establish uniform diagnostic and treatment approaches. New diagnostic as well as prognostic parameters are set to make treatment easier and more efficient. Newly identified therapeutic targets with demonstrated clinical impacts are further expected to ease the management of the disease.
For example, in 2016, the World Health Organization (WHO) updated the classification of cutaneous mastocytosis. The WHO further updated the criteria to define cutaneous involvement in cutaneous mastocytosis to differentiate it from other skin-related disorders that have cutaneous involvement.
Depending on the mutation sites, diagnosis and approach towards cutaneous mastocytosis treatment are expected to improve in the coming years. A definitive, pathogenesis-based approach towards cutaneous mastocytosis treatment may improve therapy outcome.
For example, a recent study published by the World Allergy Organization evaluated the mutation sites. Around 30% mutation sites in cutaneous mastocytosis are being reported to be exon 17 of KIT in children with cutaneous mastocytosis, whereas, another 30% children reported to have mutation outside exon 17 of KIT.
Better understanding of the pathogenesis is expected to pave the way for better management of the disease, which, in turn, is expected to fuel the growth of the cutaneous mastocytosis treatment market.
Customize this Report
Explore Intelligence Tailored to Your Business Goals.
Increasing Data Availability Allows Better Understanding
Various controlled studies are being undertaken to evaluate the actual epidemiology of cutaneous mastocytosis in different regions around the world. After the World Health Organization updated the classification, diagnosis, and treatment approach, numerous regions/countries went on to implement these very guidelines so as to improve uniformity in the diagnosis and treatment process.
As of now, the epidemiology in United States and majority of European countries is evaluated, which is helping develop a novel treatment approach. Whereas, the data availability around cutaneous mastocytosis is still limited, but the situation is improving rapidly, specifically in developed countries where the prevalence of the disease is more.
Market Research Methodology - Perfected through Years of Diligence
A key factor for our unrivaled market research accuracy is our expert- and data-driven research methodologies. We combine an eclectic mix of experience, analytics, machine learning, and data science to develop research methodologies that result in a multi-dimensional, yet realistic analysis of a market.
Cutaneous Mastocytosis Treatment Market: Competitive Landscape
This part of the report consists of the profiles of the key players in the cutaneous mastocytosis treatment market based on their market shares, product offerings, differential strategies, marketing approach, and company dashboard.
Leading pharmaceutical manufacturers in the market are focusing on enhancing their geographical product footprints, and investing in research & drug development for the cutaneous mastocytosis treatment market.
Explore Persistence Market Research’s expertise in promulgation of the business !
The Cutaneous Mastocytosis Treatment Market is Largely Fragmented with a Number of Global as Well as Regional Players
The cutaneous mastocytosis treatment market is pretty fragmented, and it is mainly dominated by large pharma companies with diverse product portfolios as well as small and medium regional players. Manufacturers in the market are focusing on developing novel treatment options for cutaneous mastocytosis, since there is no cure available currently.
Players in the cutaneous mastocytosis treatment market are competing on the basis of their regional footprint, product offerings, and prices of the drugs of same class. The cutaneous mastocytosis treatment market is dominated by Pfizer Inc., Novartis AG, Bayer AG, Merck & Co. Inc., Johnson & Johnson, and other key players.
Manufacturers are engaging in mergers and acquisitions, as well as partnering with regional small- and medium-sized players in the market. Extended efforts by various manufacturers in the cutaneous mastocytosis treatment market are expected to enhance revenue generation.
Cutaneous Mastocytosis: Definition
As per the Genetic and Rare Diseases Information Center (GARD), cutaneous mastocytosis is a heterogeneous type of rare disease that is characterized by lesions on the skin.
There are three main types of cutaneous mastocytosis - maculopapular (also called urticaria pigmentosa), diffuse cutaneous mastocytosis, and solitary cutaneous mastocytoma. The causes of this disease varies, but generally, it is caused due to mutation in the C-kit of gene. The severity of symptoms may vary depending upon the type of cutaneous mastocytosis.
Cutaneous Mastocytosis Treatment Market: About the Report
The company conducted a research study on the cutaneous mastocytosis treatment market for the forecast period 2018 to 2026. The report offers a comprehensive evaluation of the business opportunities prevailing in the cutaneous mastocytosis treatment market, with insights on the prices, current trends, prevalence of cutaneous mastocytosis, and reimbursement scenario in the cutaneous mastocytosis treatment market.
Cutaneous Mastocytosis Treatment Market: Segmentation
The report offers a comprehensive taxonomy of the market based on the drug class, route of administration, indication, distribution channel, and region. By drug class, the cutaneous mastocytosis treatment market is segmented into antihistamines, steroids, mast cell stabilizers, adrenergic agonists (epinephrine), photo-chemotherapy / psoralens (methoxsalen), and others.
By route of administration, the cutaneous mastocytosis treatment market is segmented as oral, topical, injectables, and others. By indication, the cutaneous mastocytosis treatment market is segmented into maculopapular cutaneous mastocytosis, diffuse cutaneous mastocytosis, and solitary cutaneous mastocytoma. By distribution channel, the cutaneous mastocytosis treatment market is segmented into hospitals pharmacies, retail pharmacies, online pharmacies, and drug stores.
The cutaneous mastocytosis treatment market has been analysed across the regions of North America, Latin America, Europe, Asia Pacific Excluding Japan, Japan, Oceania, and the Middle East & Africa (MEA).
Some of the additional questions addressed in this report on the cutaneous mastocytosis treatment market:
Additional Questions Answered
- What is the overall revenue generation potential of the cutaneous mastocytosis treatment market across the regions of Europe and Asia Pacific?
- Who are the key regional and global competitors? What are their portfolios in the cutaneous mastocytosis treatment market?
- What are the major challenges influencing the growth of the cutaneous mastocytosis treatment market.